MRF welcomes US MenB applications
19 June 2014
Further to the news that drugs companies Novartis and Pfizer have made applications to the US Food and Drug Administration to license their meningococcal B (Men B) vaccines, our CEO Christopher Head commented:
"We welcome the news of these Men B vaccine licence applications in the US. Meningitis Research Foundation’s vision is of a world free from meningitis and septicaemia and we believe that vaccination is the way to reach our ultimate goal. In the UK we are eagerly awaiting introduction of MenB vaccine into the childhood immunisation programme and it is encouraging to see this latest progress on protecting Americans against this deadly disease" Read more about the applications
More on MenB
In-depth Q + A on the vaccine
Hi, I’m Sam and I’m MRF's PR Manager.
If you want to know more about this story call me on 0333 405 626251, out of office hours on 07875 498047 or email email@example.com